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Structure-based development of speciﬁc inhibitors
for individual cathepsins and their medical applications
By Nobuhiko KATUNUMA*1,†
(Communicated by Takao SEKIYA, M.J.A.)
Abstract: Speciﬁc inhibitors for individual cathepsins have been developed based on their
tertiary structures of X-ray crystallography. Cathepsin B-speciﬁc inhibitors, CA-074 and CA-030,
and cathepsin L speciﬁc inhibitors, CLIK-148 and CLIK-195, were designed as the epoxysuccinate
derivatives. Cathepsin S inhibitor, CLIK-060, and cathepsin K inhibitor, CLIK-166, were
synthesized. These inhibitors can use in vitro and also in vivo, and show no toxicity for
experimental animals by the amounts used as the cathepsin inhibitor.
Various cathepsins are used in the processing of antigenic proteins. The CLIK-060 treatment
to the autoimmune disease, Sjögren model mice, led to strongly suppress the expression of the
pathological symptoms. Cathepsins L or K participates to the degradation of bone collagen. The
CLIK-148 protects osteoporosis in animals and also protects the bone metastasis of cancer cells.
Cathepsin L also enhances insulin-induced glucose uptake into 3T3-L1 adipocytes, suggesting
cathepsin L plays the roles in adipogenesis and glucose tolerance in type 2 diabetes.
Keywords: cathepsin, inhibitor, cystatin, autoimmune diseases, osteoporosis, Sjögren
syndrome
Introduction
Cysteine cathepsins make up an essential
protease family located in lysozomes of all living
cells. Eleven kinds of cysteine cathepsins have been
registered in the human genome since 2001.1) Each
cathepsin has diﬀerent cleavage bond-speciﬁcity
for substrate proteins, allowing induction of diﬀer-
ent physiological or pathological conditions. In
general, the inhibitors for all cathepsins have been
published and used, such as E-64,2)-4) leupeptin and
antipain,5),6) but no research has been published
about speciﬁc inhibitors for individual cathepsins.
We have developed speciﬁc inhibitors for indi-
vidual cathepsins in cooperation with Asao (Taiho
Pharmaceutical Co.),7)-10) by a structure-based new
drug design method using X-ray crystallography of
individual cathepsin structures (substrate binding
pocket), with epoxysuccinate (E-64) as the frame
compound. We have shown speciﬁc binding mecha-
nisms between individual cathepsins and their
corresponding synthesized inhibitors.8),11) Only CA-
074 is now commercially available from Sigma-
Aldrich Co. and is used as the cathepsin B-
speciﬁc inhibitor worldwide. Cathepsin L inhibi-
tors,7),9) CLIK-148 and CLIK-195, and cathepsin
S inhibitor, CLIK-060,7) are also being used in
many laboratories in the world and the eﬀec-
tiveness have been already published in various
journals.
Contents
Part I Structure-based development of spe-
ciﬁc inhibitors for individual cathepsins. The
classical cysteine protease inhibitors from micro-
organisms origin and natural inhibitors located in
mammalian organs, and cystatin families, were
introduced in Fig. 1.
Speciﬁc inhibitors for individual cathepsins have
been developed in our group. Cathepsin B speciﬁc
inhibitors, CA-074 and CA-030,12),13) and cathepsin L
speciﬁc inhibitors, CLIK-148 and CLIK-195,7) were
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Fig. 1. A. Development of cysteine cathepsin group speciﬁc inhibitors. a. Microorganism origin. A group of inhibitors comprise aliphatic
aldehyde and dipeptide derivatives, which was discovered by Umezawa’s group. The other inhibitor comprise epoxysuccinyl amino
acid derivatives, which was discovered by Hanada’s group2) from Aspergillus and named E-64. Main cysteine cathepsins and these
inhibitors were discovered at the same time, between 1980 and 2000.2),3) b. Mammalian origin (cystatin family). Most cystatin families
have a molecular weight of about 10,000; the high molecular weight inhibitors, kininogen group that participates in blood coagulation
is characterized with a high molecular weight of the cystatin conjugates. B. Development of speciﬁc inhibitors for individual
cathepsins by structure-based designs from tertiary structures of the binding pocket of cathepsins using their X-ray crystal structures,
which were developed by Katunuma’s group. Cathepsin B-speciﬁc inhibitors (CA-074 and CA-030) and cathepsin L-speciﬁc inhibitors
(CLIK 148 and CLIK-195) were designed E-64 as a frame. Cathepsin S-speciﬁc inhibitor (CLIK-060) was designed based on the
structure of leupeptin and antipain. Cathepsin K-speciﬁc inhibitors (CLIK-163) was designed from pyridoxal phosphate.
N. KATUNUMA [Vol. 87, 30developed from the structure of epoxysuccinate
derivatives as the frame compound. These derivatives
were designed as individual cathepsin inhibitors,
using X-ray crystallography of the tertiary structure
of their substrate binding pocket.8),11),14)
As summarized in Table 1, CA-030 and CA-074
speciﬁcally inhibit cathepsin B at 10!7M, and CLIK-
148 and CLIK-195 inhibit cathepsin L7) at 10!6M,
CLIK-060 inhibits cathepsin S7) at 10!6M, and
CLIK-164 inhibits cathepsin K9) at 10!5M. Cathe-
psin K inhibitor CLIK-164 is a pyridoxal deriva-
tives;9) and cathepsin K inhibitor CLIK-166 is an
aromatic vinyl-derivative of pyridine ring. Their
chemical structures are illustrated in Fig. 1B.
Cathepsin B-speciﬁc inhibitor, CA-030, is ex-
plained here as a typical example of structure-based
inhibitor design11),14) that uses X-ray crystallograp-
ical data of cathepsin B. The binding structure of
cathepsin B with CA-030 is shown in Fig. 2. The
substrate or inhibitor is inserted into the substrate
binding pocket in the vertical way. The upper part of
the substrate binding pocket of cathepsin B is closed
by a large occluding loop, and two moles of histidines
are located side by side at the positions 110 and 111
to form an area of strong positive charge. Therefore,
a proline was designed in the C-terminus of CA-074
and CA-030 to bind with the strong positive charges
of these histidines in the occluding loop. When an
epoxysuccinyl isoleucine is bound next to the proline,
the epoxysuccinyl group of the inhibitor can easily
approach Gln-23 located on the surface of the
substrate binding pocket of cathepsin B to make
an oxyanion hole. As a result, the active site of the
Cys-29 of cathepsin B easily binds with that of
epoxysuccinate; while other cathepsins do not possess
such an occluding loop in the substrate binding
pocket.
The mechanisms of speciﬁc binding of CLIK-
148 with cathepsin L can be shown by X-ray co-
crystallography (Fig. 3).8) The Try-189 is located at
the end (bottom) of the substrate binding area which
forms a hydrophobic area. The epoxysuccinate of
CLIK-148 can easily bind with the active site of Cys-
25 of cathepsin L, and the epoxysuccinate of CLIK-
148 binds to Gln-19 to make an oxyanion hole. Thus,
CLIK-148 binds very tightly and speciﬁcally with
cathepsin L.
The aromatic aldehyde attached to pyridoxal-3
propionate derivatives shows a speciﬁca ﬃnity to
cathepsin K. Cathepsin K-speciﬁc inhibitor, CLIK-
164,9) an aromatic aldehyde derivatives. The cathe-
psin S-speciﬁc inhibitor, CLIK-060,7) have been
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Fig. 2. Schematic presentation of CA-030 binding with cathepsin
B. Proline on the C-terminus of CA-030 has strong aﬃnity for
histidines (2mol) located in the occluding loop of cathepsin B.
CA-030 forms an oxyanion hole with Gln-23 in the binding
pocket of cathepsin B.
Table 1. Inhibition speciﬁcities for various cathepsins
Inhibition
concentration
Cathepsins
10!XMBLSK
CA-030 !7 100 0 0 0
CA-074 !7 100 0 0 0
CLIK-148 !6 0 100 30 0
!70 6 3 0 0
CLIK-195 !6 0 100 25 0
!70 8 5 0 0
CLIK-060 !6 25 30 100 10
!70 0 8 6 0
CLIK-164 !5 0 20 60 100
!60 0 2 0 6 0
CLIK-166 !4 0 0 17 100
!5 000 1 0 0
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Fig. 4. Class-switch Th-cell responses of antigen processing by diﬀerent cathepsins.
Fig. 3. Schematic illustration of speciﬁc binding of CLIK-148 with cathepsin L by X-ray co-crystallography.
N. KATUNUMA [Vol. 87, 32synthesized as an aldehyde derivatives. These inhib-
itors show strong and speciﬁc inhibition with their
individual cathepsins both in vitro and in vivo at
10!6–10!7M (Table 1). They do not show any
considerable toxicity at their inhibition concentra-
tions used in rats and mice.
Part II Medical applications of speciﬁc in-
hibitors for individual cathepsins. These speciﬁc
inhibitors of individual cathepsins are useful for
analyzing biological roles of cathepsins, such as the
clariﬁcation of the pathogenesis of various diseases
mediated by abnormal expression of speciﬁc cathe-
Fig. 5. Changes in ovalbumin dependent production of anti-
bodies and cytokines by administration of cathepsin B inhibitor
(CA-074). The ovalbumin dependent production of antibodies
and cytokines was class-switched by the administration of CA-
074. Type 2 responses were suppressed, while type 1 responses
were enhanced.
Fig. 6. Immune response (stimulation index) of Sjögren syndrome through auto-antigen ,-fodrin processing by cathepsin S and its
suppression by CLIK-060. Using Sjögren model mice, the stimulation index of thymidine incorporation was determined. ,-Fodrin
(but not ovalbumin) speciﬁcally stimulated the index and cathepsin S inhibitor CLIK-060 speciﬁcally suppressed it.
Table 2. Pathological symptoms of Sjögren syndrome model
mice and their suppression by CLIK-060
Pathological legion grade
Grade of legions
Lacrimal G Submandibular G
non-Tx SS 0.3 0.3
Tx 3.8 3.0
SS D CA-074 2.8 2.5
SS D CLIK-148 3.5 2.8
SS D CLIK-060 0.9 1.0
Secretion volume of saliva and tears
Saliva Tears
non-Tx SS 9.0 3.0
Tx 2.0 1.0
SS D CLIK-060 7.0 2.9
Non-Tx-SS: Non-thymectomized Sjögren model mice.
Tx-SS: Thymectomized Sjögren model mice.
Secretion volume given in µl/20min.
The morphological pathological legion in lacrimal gland and
submandibular glands were prevented by cathepsin S inhib-
itor, CLIK-060, but not by the other inhibitors tested.
Secretion volume of saliva and tears were decreased dramat-
ically in the disease model animals, but the treatment of CLIK-
060 prevented these Sjögren syndromes to the normal levels, as
shown in Table 2.
Speciﬁc inhibitors for individual cathepsins and their medical applications No. 2] 33psins, and for development of powerful therapeutic
drugs that originated from abnormal expression of
special cathepsins.
(a) Regulation of antigen processing by various
cathepsins and the class switch of Th-cell responses
by corresponding cathepsin inhibitors.15)–19) Antigen
processing by cathepsins and the epitope presenta-
tion to major histocompatibility complex (MHC)
class II are shown in Fig. 4. The invariant chain
binding to MHC class II molecules was removed
by cathepsins S and D, and exogenous antigens
are processed by various cathepsins. Therefore,
diﬀerent cathepsins produce diﬀerent epitopes,
even if processed from the same antigen, as shown
Fig. 7. Mechanisms of osteoclastic bone resorption and pit formation by the cultured pit formation test (upper). Pit formation was
stimulated by TNF-, addition and inhibited by cathepsin L inhibitor CLIK-148 addition (under).
N. KATUNUMA [Vol. 87, 34in Fig. 5. For instance, when cathepsin B partic-
ipates in antigen processing to stimulate Th2
responses, IgG2a and .-IFN production were pro-
moted and IgE, IgG1 and IL-4 production were
suppressed. Thus, classes of immune responses are
switched between Th1 cells and Th2 cells by
diﬀerent cathepsin inhibitors, as shown in Figs. 4
and 5.
(b) Autoimmune diseases.20),21) Autoimmune
diseases are expressed by the presence of a special
epitope derived from an auto-antigen processed by a
particular cathepsin. Therefore, inhibition of auto-
antigen processing by a special cathepsin can inhibit
auto-antibody production, suppressing the expres-
sion of the autoimmune disease. A typical auto-
immune disease, Sjögren syndrome, was expressed by
the processing of auto-antigen “,-fodrin” by cathe-
psin S, producing the responsible auto-antibody in a
Sjögren mouse model. Cathepsin S inhibitor CLIK-
060 speciﬁcally suppressed the expression of Sjögren
syndrome (Fig. 6). Cell proliferation responses by ,-
fodrin in Sjögren model mice could be completely
suppressed by cathepsin S inhibitor, but not by other
cathepsin inhibitors and Sjögren syndrome could be
almost completely subsided by CLIK-060 treatment
(Table 2). No other therapy than glucocorticoid
AB
Fig. 8. Bone metastasis of cancer cells by secreted cathepsin L and its suppression by CLIK-148. A. Ca release from mouse calvaria by
invasion of colon tumor-26 PMF-15 cells and its protection by CLIK-148 treatment. B. Melanoma cells (A357) were injected into the
left ventricle of the heart causing distant bone metastasis via systemic circulation.
Speciﬁc inhibitors for individual cathepsins and their medical applications No. 2] 35hormone administration is currently available for
autoimmune diseases, but long term treatment of
glucocorticoid hormone is not recommended, cathe-
psin S-speciﬁc inhibitor may provide a potential
eﬀective treatment.20),21)
(c) Protection of osteoporosis and bone metastasis
of cancer.10),22)–24) Bone and teeth mainly consist
of type I collagen, which is mainly degraded by
cathepsins L or K. Both cathepsins are therefore
referred to as “collagenolytic cathepsins”.25) Some
cancer cells secrete large amounts of collagenolytic
cathepsins playing an important role in cancer
metastasis and invasion in bone. Administration of
inhibitor for cathepsin L or K has been shown
signiﬁcant protection against cancer metastasis and
invasion in bone. An example of the pit formation
mechanisms is shown in Fig. 7.26)
Inoculation of colon tumor 26PMF-15 cells into
mouse calvaria resulted in 60–70% calcium released
from the calvaria. This calcium release can be
protected by CLIK-148 administration, as shown in
Fig. 8A. Distant bone metastasis of melanoma cells
A375, is illustrated in Fig. 8B. Upon injection into
the left ventricles of rat hearts and the cancer cells
were transported through the systemic circulation,
the melanoma cells implant on the distant bone
surface and make bone lacunue via osteoclasts. The
CLIK-148 treatment protected half (50%) of these
metastatic focuses formation (Fig. 8B). Bone degra-
dation was mainly the result of osteoclasts which
are located on the surface of bone, secreting large
amounts of cathepsins L and K. On the contrary,
parathyroid hormone can stimulate the metastasis.
These cathepsins are secreted into bone acidic lacuna
by the help of ATP proton pump by carbonic
anhydrase. Therefore, administration of CLIK-148
and/or carbonic anhydrase inhibitors could suppress
bone pit formation.
(d) Cathepsin L activity controls adipogenesis and
glucose tolerance.23) In vitro studies demonstrate
the role of cathepsin L in the degradation of the
matrix protein ﬁbronectin, insulin receptor (IR) and
insulin-like growth factor-1 receptor (IGF-IR), essen-
tial molecules for adipogenesis and glucose metabo-
lism. Cathepsin L inhibition leads to the reduction
of human and murine pre-adipocyte adipogenesis
or lipid accumulation, protection of ﬁbronectin
from degradation, accumulation of IRO and IGF-
IRO subunits, and an increase in glucose uptake
(Fig. 9).23) Cathepsin L-deﬁcient mice are lean and
have reduced levels of serum glucose and insulin, but
increased levels of muscle IRO subunit, ﬁbronectin
and glucose transporter (Glut-4). Inhibition of
cathepsin L by administration of CLIK-148 also
demonstrated reduced body weight gain and serum
insulin levels, and increased glucose tolerance due to
increased levels of muscle IRO subunit, ﬁbronectin,
and Glut-4 in both diet-induced obese mice and ob/
ob mice. Increased levels of cathepsin L in obese and
diabetic patients suggest that cathepsin L is a novel
target for these metabolic disorders.
Perspective and anticipation in the future
(Discussion)
(1) These chemically synthesized inhibitors show
no particular toxicity in experimental animals,
although long term toxicity needs further study.
The eﬀect on humans is also a major topic of
future studies.
(2) Inhibition speciﬁcities of some individual cath-
epsin inhibitors need to be improved. CA-074
and CA-030 (cathepsin B inhibitors) show
absolute speciﬁcity at 10!7M, while CLIK-148
and CLIK-195 (cathepsin L inhibitors) show
high speciﬁcity at 10!7M. However, CLIK-060
(cathepsin S inhibitor) show 86% inhibition at
10!7M, while CLIK-060 is unstable. CLIK-164
and CLIK-166 (cathepsin K inhibitors) requires
a concentration of 10!5M. Cathepsin S inhibitor
Fig. 9. Cathepsin L inhibition with CLIK-195 enhanced insulin-
induced glucose uptake into 3T3-L1 adipocytes.23) Data
represent glucose uptake (cpm) fold-increases relative to the
cpm counts for cells treated with no insulin and no inhibitors.
N. KATUNUMA [Vol. 87, 36and cathepsin K inhibitor need further improve-
ment in sensitivity and stability.
(3) Immunity or suppression of IgE allergy expres-
sion needs to be reinforced. Cathepsin B
inhibitor (CA-074 or CA-030) administration
can be used for suppression of IgE allergy.
(4) No eﬀective therapy other than glucocorticoid
hormone administration is available for auto-
immune diseases at present in general. Incidence
mechanisms have been clariﬁed for autoimmune
diseases, i.e., Sjögren syndrome. Therefore,
cathepsin S inhibitors (CLIK-060) should be
used in a clinical setting. This principal can use
for other autoimmune diseases in general.
(5) Cathepsin inhibitors have been synthesized by
Taiho Pharmaceutical Co. in cooperation with
Katunuma. Only CA-074, as a cathepsin B-
speciﬁc inhibitor, is now commercially available
from Sigma-Aldrich Co. Other cathepsin inhib-
itors (CLIKs) should be synthesized as com-
mercially available products.
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